BioArctic AB Company Description
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden.
It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs.
The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases.
In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies.
Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage.
It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016.
BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Gunilla Osswald |
Contact Details
Address: Warfvinges vag 35 Stockholm, 112 51 Sweden | |
| Phone | 46 86 95 69 30 |
| Website | bioarctic.se |
Stock Details
| Ticker Symbol | BRCTF |
| Exchange | OTCMKTS |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010323311 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gunilla Osswald Ph.D. | President and Chief Executive Officer |
| Dr. Pär Gellerfors | Co-Founder, Senior Vice President of Business Strategy and Director |
| Prof. Lars Lannfelt | Co-Founder, Senior Vice President of Medical science and Director |
| Anders Martin-Lof M.B.A., M.Sc. | Chief Financial Officer |
| Johanna Fälting | Chief Research & Development Officer and Head of Research and Development |
| Christer Möller | Vice President of Pre-Clinical Development and Chief Scientific Officer |
| Oskar Bosson | Vice President and Head of IR and Communication |
| Leif Gallo LL.M. | General Counsel and Head of Legal and IP |
| Harald Borgeke | Head of Public Affairs |
| Frida Lekander | Head of Marketing |